Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Progyny, Inc.
PGNY
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $2.3B
$30.22
▲ +2.61%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$16.10 - $30.33
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 38.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized expertise in fertility and family building benefits with differentiated plan design
- Integrated concierge-style member support services creating high engagement and retention
- Selective network of vetted fertility specialists ensuring quality care and cost management
- Comprehensive integrated platform combining medical, pharmacy, and family building benefits
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Stable outlook
Increasing employer demand for fertility benefits as talent acquisition and retention tool
Value
Significant premium - growth priced in
Momentum
Hot
+77.4% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying PGNY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $0.30 vs $0.26 consensus (+17.2% surprise). Revenue of $328.5M vs $326.5M expected (+0.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+17.2%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+11%
+17%
+9%
+9%
+7%
+1%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$304.1M
$286.6M
$298.4M
$324.0M
$332.9M
$313.3M
$318.4M
$328.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
7.4%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$27.00
▼ -10.7% vs $30.22
Latest: Canaccord · $30.00 · May 19, 2026
2 analysts covering